BioXcel Therapeutics Shares Surge 34% as Phase 3 SERENITY Trial Advances and Equity Raise
By ATTN Desk · Editorial oversight: Sean Han
Introduction
BIOXCEL THERAPEUTICS INC (Nasdaq: BTAI) is a Connecticut-based biopharmaceutical company founded in 2017. The company leverages artificial intelligence to develop therapies in neuroscience and immuno-oncology. As of August 8, 2025, its share price closed at $4.5699, reflecting a 34.01% increase from the prior session, on a volume of 19,920,190 shares traded.
| Metric | Value |
|---|---|
| Ticker | BTAI |
| Exchange | Nasdaq (NAS) |
| Price (08/08/2025 close) | $4.5699 |
| Daily Change | +34.01% |
| Volume | 19,920,190 |
| 52-Week Range | $1.17 – $13.60 |
| Market Cap (intraday) | $24.46 M |
Corporate Structure
Headquartered in New Haven, Connecticut, BioXcel employs between 51 and 200 people. Its organizational focus includes pharmaceutical research, clinical pharmacology, R&D, and AI-driven drug discovery. Key specialties comprise neuroscience, immuno-oncology, and big data analytics. The company operates under its parent entity and a subsidiary, OnkosXcel Therapeutics LLC, to advance both neuroscience and oncology pipelines.
Biopharmaceuticals by Kelly Sikkema
Recent Developments and News
- August 6, 2025: A publication in Frontiers in Pharmacology detailed non-clinical data on dexmedetomidine (the active ingredient in BXCL-501), which demonstrated modulation of stress-mediated behaviors.
- August 6, 2025: Filed a Prospectus Supplement (Rule 424(b)(5)) to increase its at-the-market equity offering by up to $3.5 million. To date, $8.135 million in shares have been sold under this program; the public float stands at approximately $35.9 million (12,085,257 non-affiliate shares).
- Phase 3 SERENITY At-Home Trial: An independent Data Safety Monitoring Board granted a positive recommendation, permitting continuation of the pivotal trial for acute treatment of agitation in bipolar disorders and schizophrenia without protocol modifications after reviewing safety data from 178 patients dosed through May 28, 2025.
- August 1, 2025: IGALMI® was registered as a trademark of BioXcel Therapeutics, Inc., covering the oral film formulation of dexmedetomidine for acute agitation in schizophrenia and bipolar I/II disorder.
Financial and Strategic Analysis
BioXcel’s capital-raising through its equity distribution agreement indicates a strategy to fund ongoing clinical trials and pipeline advancement. Key financial and valuation metrics (TTM) include:
- Price/Sales: 6.00
- Enterprise Value/Revenue: 51.57
- Cash on Hand (mrq): $31.01 M
- Net Income (TTM): –$40.06 M
- EPS (TTM): –$11.12
Although the company operates at a net loss, its cash position and access to incremental equity capital are intended to support near-term funding for the SERENITY trial and other programs. BXCL-501 has received FDA Breakthrough Therapy designation for dementia-related agitation and Fast Track status for agitation in schizophrenia, bipolar disorders, and dementia, with a potential label extension filing expected by the end of 2025.
Market Position and Industry Context
Within the biotech sector, BioXcel employs AI-enabled discovery platforms and maintains a dual focus on neuroscience and immuno-oncology. Its lead asset, BXCL-501, targets acute agitation across multiple neuropsychiatric indications. The stock experienced a 52-week high of $13.60 in 2024 and a low of $1.17 in May 2025, indicative of the clinical and financial volatility typical of small-cap biotech firms. The five-year beta is 0.06, suggesting limited correlation with broader market movements. An average daily volume of 5.11 million shares indicates notable investor interest alongside trial readouts.
TL;DR
– On August 6, 2025, BioXcel published non-clinical data on BXCL-501’s active ingredient in Frontiers in Pharmacology.
– The company secured a Prospectus Supplement to raise up to $3.5 million through at-the-market equity sales, with an aggregate of $8.135 million sold to date.
– An independent DSMB authorized continuation of the Phase 3 SERENITY At-Home trial for agitation in bipolar and schizophrenia after reviewing safety data through May 28, 2025.
– BXCL-501 holds FDA Breakthrough and Fast Track designations; a label extension filing is anticipated by year-end 2025.